[Featured Stock] Suzentec Secures Clinical Samples for Wuhan Pneumonia through MOU with Wuhan-Based Biotech Company

[Asia Economy Reporter Hyungsoo Park] SuzenTech's stock price has been rising sharply recently.

As of 10:56 AM on January 29, SuzenTech is trading at 9,010 KRW, up 16.41% from the previous day.

SuzenTech announced that it will collaborate with Humanwell Healthcare Group, headquartered in Wuhan, China, to develop a 'rapid diagnostic kit' for diagnosing 'Wuhan pneumonia.'

SuzenTech and Humanwell Biosell have agreed to develop a rapid diagnostic kit that can quickly diagnose the presence of the novel coronavirus infection, which started in Wuhan, China and is spreading rapidly, through antigen or antibody testing from throat and pharyngeal specimens on-site. SuzenTech will be responsible for developing antibodies, pretreatment reagents, and kits, while Biosell will handle clinical trials, production, and sales by securing specimens within China.

A SuzenTech representative explained, "Biosell, based in Wuhan, will be able to quickly secure clinical specimens," adding, "We expect to develop a dedicated diagnostic kit for Wuhan pneumonia faster than other diagnostic companies.”